METASTRON

Metastron Adverse Events Reported to the FDA Over Time

How are Metastron adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Metastron is flagged as the suspect drug causing the adverse event.

Most Common Metastron Adverse Events Reported to the FDA

What are the most common Metastron adverse events reported to the FDA?

Anaemia	93 (8.56%)
Condition Aggravated	80 (7.37%)
Platelet Count Decreased	57 (5.25%)
Disease Progression	44 (4.05%)
Disseminated Intravascular Coagulat...	41 (3.78%)
White Blood Cell Count Decreased	26 (2.39%)
Bone Marrow Failure	25 (2.3%)
Malignant Neoplasm Progression	23 (2.12%)
No Adverse Event	21 (1.93%)
General Physical Health Deteriorati...	18 (1.66%)
Nausea	16 (1.47%)
	Show More
Pain	16 (1.47%)
Neoplasm Progression	15 (1.38%)
Haemoglobin Decreased	14 (1.29%)
Hot Flush	14 (1.29%)
Bone Pain	13 (1.2%)
Prostate Cancer	13 (1.2%)
Pyrexia	13 (1.2%)
Death	12 (1.1%)
Diarrhoea	12 (1.1%)
Pneumonia	11 (1.01%)
Interstitial Lung Disease	9 (.83%)
Malaise	9 (.83%)
Metastatic Pain	9 (.83%)
Sepsis	9 (.83%)
Asthenia	8 (.74%)
Depressed Level Of Consciousness	8 (.74%)
Lung Neoplasm Malignant	8 (.74%)
Prostate Cancer Metastatic	8 (.74%)
Thrombocytopenia	8 (.74%)
Metastases To Liver	7 (.64%)
Vomiting	7 (.64%)
Blood Albumin Decreased	6 (.55%)
Blood Pressure Decreased	6 (.55%)
Decreased Appetite	6 (.55%)
Headache	6 (.55%)
Pancytopenia	6 (.55%)
Protein Total Decreased	6 (.55%)
Back Pain	5 (.46%)
Breast Cancer Female	5 (.46%)
Delirium	5 (.46%)
Gastrointestinal Haemorrhage	5 (.46%)
Hepatic Function Abnormal	5 (.46%)
Malignant Pleural Effusion	5 (.46%)
Red Blood Cell Count Decreased	5 (.46%)
Respiratory Failure	5 (.46%)
Anorexia	4 (.37%)
Bone Marrow Tumour Cell Infiltratio...	4 (.37%)
Breast Cancer Metastatic	4 (.37%)
Colon Cancer	4 (.37%)
Concomitant Disease Aggravated	4 (.37%)
Dyspnoea	4 (.37%)
Gait Disturbance	4 (.37%)
Metastases To Bone	4 (.37%)
Oesophageal Candidiasis	4 (.37%)
Pleural Effusion	4 (.37%)
Somnolence	4 (.37%)
Subdural Haemorrhage	4 (.37%)
Urinary Tract Infection	4 (.37%)
Abdominal Pain Upper	3 (.28%)
Acute Respiratory Distress Syndrome	3 (.28%)
Anorectal Disorder	3 (.28%)
Bladder Disorder	3 (.28%)
Blood Alkaline Phosphatase Increase...	3 (.28%)
Blood Calcium Increased	3 (.28%)
Blood Urea Increased	3 (.28%)
Cerebral Infarction	3 (.28%)
Cholecystitis	3 (.28%)
Constipation	3 (.28%)
Dehydration	3 (.28%)
Dementia	3 (.28%)
Dizziness	3 (.28%)
Eating Disorder	3 (.28%)
Fall	3 (.28%)
Fatigue	3 (.28%)
Gastritis	3 (.28%)
Haematuria	3 (.28%)
Hypercalcaemia	3 (.28%)
Hypoaesthesia	3 (.28%)
Leukaemia	3 (.28%)
Lung Cancer Metastatic	3 (.28%)
Monoplegia	3 (.28%)
Multi-organ Failure	3 (.28%)
Neoplasm Malignant	3 (.28%)
Oedema	3 (.28%)
Pathological Fracture	3 (.28%)
Prostatic Specific Antigen Increase...	3 (.28%)
Pulmonary Oedema	3 (.28%)
Septic Shock	3 (.28%)
Tumour Haemorrhage	3 (.28%)
Acute Myeloid Leukaemia	2 (.18%)
Acute Promyelocytic Leukaemia	2 (.18%)
Alanine Aminotransferase Increased	2 (.18%)
Altered State Of Consciousness	2 (.18%)
Alveolitis Allergic	2 (.18%)
Aspartate Aminotransferase Increase...	2 (.18%)
Blood Glucose Increased	2 (.18%)
Blood Potassium Increased	2 (.18%)
Blood Sodium Decreased	2 (.18%)
Breast Cancer	2 (.18%)
Cachexia	2 (.18%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metastron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Metastron

What are the most common Metastron adverse events reported to the FDA?

Anemias Nonhemolytic And Marrow Dep...	124 (11.42%)
Hematology Investigations	109 (10.04%)
Miscellaneous And Site Unspecified ...	42 (3.87%)
Coagulopathies And Bleeding Diathes...	41 (3.78%)
Infections - Pathogen Unspecified	32 (2.95%)
Gastrointestinal Signs	29 (2.67%)
Neurological	25 (2.3%)
Reproductive Neoplasms Male Maligna...	21 (1.93%)
Lower Respiratory Tract Disorders	20 (1.84%)
Neoplasm Related Morbidities	18 (1.66%)
Bone Disorders	16 (1.47%)
	Show More
Metastases	16 (1.47%)
Gastrointestinal Motility And Defec...	15 (1.38%)
Protein And Chemistry Analyses	14 (1.29%)
Vascular	14 (1.29%)
Body Temperature Conditions	13 (1.2%)
Fatal Outcomes	13 (1.2%)
Gastrointestinal Neoplasms Malignan...	13 (1.2%)
Appetite And General Nutritional	12 (1.1%)
Cardiac And Vascular Investigations	12 (1.1%)
Gastrointestinal Hemorrhages	12 (1.1%)
Respiratory And Mediastinal Neoplas...	12 (1.1%)
Breast Neoplasms Malignant And Unsp...	11 (1.01%)
Injuries	11 (1.01%)
Respiratory	11 (1.01%)
Water, Electrolyte And Mineral	10 (.92%)
Platelet	8 (.74%)
Hepatic And Hepatobiliary	7 (.64%)
Leukemias	7 (.64%)
Central Nervous System Vascular	6 (.55%)
Deliria	6 (.55%)
Electrolyte And Fluid Balance Condi...	6 (.55%)
Headaches	6 (.55%)
Movement Disorders	6 (.55%)
Musculoskeletal And Connective Tiss...	6 (.55%)
Bone And Joint Injuries	5 (.46%)
Bone, Calcium, Magnesium And Phosph...	5 (.46%)
Gastrointestinal Ulceration And Per...	5 (.46%)
Hepatobiliary	5 (.46%)
Bacterial Infectious	4 (.37%)
Cardiac Arrhythmias	4 (.37%)
Enzyme	4 (.37%)
Epidermal And Dermal Conditions	4 (.37%)
Fungal Infectious	4 (.37%)
Gastrointestinal Inflammatory Condi...	4 (.37%)
Hematopoietic Neoplasms	4 (.37%)
Pleural	4 (.37%)
Renal And Urinary Tract Investigati...	4 (.37%)
Therapeutic And Nontherapeutic Effe...	4 (.37%)
Urinary Tract Signs	4 (.37%)
Anal And Rectal Conditions	3 (.28%)
Bladder And Bladder Neck Disorders	3 (.28%)
Decreased And Nonspecific Blood Pre...	3 (.28%)
Eating Disorders	3 (.28%)
Fractures	3 (.28%)
Gallbladder	3 (.28%)
Immunology And Allergy	3 (.28%)
Mental Impairment	3 (.28%)
Metabolic, Nutritional And Blood Ga...	3 (.28%)
Oral Soft Tissue Conditions	3 (.28%)
Renal Disorders	3 (.28%)
Dental And Gingival Conditions	2 (.18%)
Endocrine Neoplasms Malignant And U...	2 (.18%)
Gastrointestinal Stenosis And Obstr...	2 (.18%)
Hepatobiliary Neoplasms Malignant A...	2 (.18%)
Musculoskeletal And Soft Tissue Inv...	2 (.18%)
Pulmonary Vascular	2 (.18%)
Renal And Urinary Tract Neoplasms M...	2 (.18%)
Renal And Urinary Tract Therapeutic...	2 (.18%)
Reproductive Tract	2 (.18%)
Spinal Cord And Nerve Root	2 (.18%)
Upper Respiratory Tract Disorders	2 (.18%)
Administration Site Reactions	1 (.09%)
Cardiac Disorder Signs	1 (.09%)
Disturbances In Thinking	1 (.09%)
Gastrointestinal Conditions	1 (.09%)
Heart Failures	1 (.09%)
Inner Ear And Viiith Cranial Nerve	1 (.09%)
Joint	1 (.09%)
Lifestyle Issues	1 (.09%)
Microbiology And Serology	1 (.09%)
Muscle	1 (.09%)
Ocular Neuromuscular	1 (.09%)
Peritoneal And Retroperitoneal Cond...	1 (.09%)
Procedural And Device Related Injur...	1 (.09%)
Protein And Amino Acid Metabolism	1 (.09%)
Skin Vascular Abnormalities	1 (.09%)
Sleep Disorders	1 (.09%)
Structural Brain	1 (.09%)
Tissue	1 (.09%)
Vascular Hemorrhagic	1 (.09%)
Vitamin Related	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Metastron, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metastron is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.